The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. All that said, here are three overhyped stocks that may correct and some you should consider instead.

Hexcel (HXL)

One-Month Return: +11%

Founded shortly after World War II by a group of engineers from UC Berkley, Hexcel (NYSE: HXL) manufactures lightweight composite materials primarily for the aerospace and defense sectors.

Why Are We Out on HXL?

1. Sales trends were unexciting over the last five years as its 1.2% annual growth was below the typical industrials company
2. Flat earnings per share over the last two years underperformed the sector average
3. Low returns on capital reflect management’s struggle to allocate funds effectively

At $81.10 per share, Hexcel trades at 37.6x forward P/E. Read our free research report to see why you should think twice about including HXL in your portfolio.

Omnicell (OMCL)

One-Month Return: +15.8%

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ: OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Why Do We Think OMCL Will Underperform?

1. Sales were flat over the last two years, indicating it’s failed to expand this cycle
2. Efficiency has decreased over the last five years as its adjusted operating margin fell by 9.5 percentage points
3. Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 5.4% annually

Omnicell is trading at $50.78 per share, or 28.4x forward P/E. If you’re considering OMCL for your portfolio, see our FREE research report to learn more.

IQVIA (IQV)

One-Month Return: +9.1%

Created from the 2016 merger of Quintiles (a clinical research organization) and IMS Health (a healthcare data specialist), IQVIA (NYSE: IQV) provides clinical research services, data analytics, and technology solutions to help pharmaceutical companies develop and market medications more effectively.

Why Are We Cautious About IQV?

1. Annual sales growth of 3.5% over the last two years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand
2. Constant currency growth was below our standards over the past two years, suggesting it might need to invest in product improvements to get back on track
3. 3.6 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position

IQVIA’s stock price of $242.50 implies a valuation ratio of 19.3x forward P/E. To fully understand why you should be careful with IQV, check out our full research report (it’s free).

Stocks We Like More

Check out the high-quality names we’ve flagged in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.